Medical-device maker Boston Scientific (NYSE:BSX) yesterday released data from a clinical trial showing that its Promus Element drug-eluting stent showed advantages over Abbott's (NYSE: ABT) Xience V drug-eluting stent with less blood vessel straightening over a three-year period.

The Promus Element also demonstrated less unplanned or emergency stenting as compared with the Xience V, in line with earlier data, along with a lower rate of inadequate lesion coverage, among other advantages. Separate data showed less vessel straightening with the Promus Element, which can lead to improved blood flow, according to Boston Scientific.

The FDA first approved the Promus Element Plus Stent System in 2011; Boston Scientific's system earlier picked up CE Mark approval in 2009.